Accessibility Menu
Nephros logo

Nephros(NASDAQ) NEPH

Current Price$3.67
Market Cap$39.52MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)-100%
5 Year-61%
1 Year+6%
1 Month+9%
Nephros last closing stock price
MetricPriceDate
Last closeUSD 3.642026-07-24
Nephros stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.7%USD 3.782026-07-17
1 month+8.66%USD 3.352026-06-24
3 month+26.83%USD 2.872026-04-24
Year to date-25.41%USD 4.882025-12-31
1 year+5.81%USD 3.442025-07-24
3 year+169.63%USD 1.352023-07-25
5 year-61%USD 9.332021-07-23
Since inception-99.65%USD 1,053.002004-09-21

Nephros Financials at a Glance

Market Cap

$39.52MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$19.12M

Net Income (TTM)

$776.00K

EPS (TTM)

$0.07

P/E Ratio

51.49

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Price

$3.67

Volume

38

Open

$3.50

Previous Close

$3.67

Daily Range

$3.45 - $3.67

52-Week Range

$2.66 - $6.42

Estimated Earnings Date

Aug 6, 2026

NEPH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nephros

Nephros, Inc. is a commercial-stage company specializing in innovative water filtration solutions for medical and commercial sectors. Founded by healthcare professionals, Nephros focuses on safeguarding water quality by eliminating pathogens, thereby ensuring safety in environments such as hospitals and dialysis centers where water quality is critical. The company also caters to commercial markets like food service and hospitality, improving water taste, odor, and reducing contaminants. Nephros leverages strong relationships with value-added resellers to expand market reach, supporting sustained growth in its niche markets.

Products and Services

Ultrafilters for hospitals and dialysis centers, capturing contaminants as small as 0.005 microns.

Commercial water filters improving taste and odor, reducing biofilm, bacteria, and scale.

NanoGuard and commercial filters for hotels, restaurants, and convenience stores.

Medical-grade products like DSU-H, SSU-H, S100, HydraGuard, and EndoPur with FDA clearances.

Potential exploration of hemodiafiltration (HDF) device opportunities in the future.

What Makes Nephros, Inc. Special

Nephros excels in ultrafiltration technology, providing one of the smallest pore sizes in the industry, which ensures superior removal of pathogens. This focus on high-performance, reliable water filtration systems gives them a competitive edge in medical-grade applications and extends to other commercial markets.

Five Things You Need to Know

Nephros' ultrafilters are instrumental in infection control across over 6,129 U.S. hospitals.

Partnerships with value-added resellers enhance distribution in medical and commercial sectors.

Nephros' medical devices have FDA 510(k) clearances ensuring compliance with safety regulations.

Commercial products target taste and odor improvement, broadening appeal beyond medical markets.

Strategic growth through innovation and R&D aligns with evolving regulatory and market demands.

AI Generated • Apr 16, 2026

Industry

Machinery

Sector

Industrials

Employees

36

CEO

Robert Banks, MBA

Website

www.nephros.com

Headquarters

South Orange, NJ 07079, US

NEPH Financials

Key Financial Metrics (TTM)

Gross Margin

59.06%

Operating Margin

3.54%

Net Income Margin

4.06%

Return on Equity

7.66%

Return on Capital

10.17%

Return on Assets

5.63%

Earnings Yield

1.94%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$39.52MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

10.86M

Volume

38

Avg. Volume

19.20K

Financials (TTM)

Gross Profit

$11.30M

Operating Income

$677.00K

EBITDA

$857.00K

Operating Cash Flow

-$348.00K

Capital Expenditure

$0.00

Free Cash Flow

-$348.00K

Cash & ST Invst.

$4.02M

Total Debt

$968.00K

Nephros Performance Analysis

Nephros annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 9,975,000-2.4%
20232023-12-31USD 14,238,00042.7%
20242024-12-31USD 14,162,000-0.5%
20252025-12-31USD 18,789,00032.7%
Nephros sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-9.4%
Q32025-09-307.8%
Q42025-12-31-0.7%
Q12026-03-3110.2%
Nephros annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.7274.9%
20232023-12-31USD -0.15-78.9%
20242024-12-31USD 0.01N/A
20252025-12-31USD 0.111455.7%
Nephros sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-58.4%
Q32025-09-3039.3%
Q42025-12-31-82.0%
Q12026-03-31130.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$5.21M

+6.9%

Gross Profit

$2.96M

-6.0%

Gross Margin

56.87%

N/A

Market Cap

$39.52MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.10M

N/A

Employees

36

N/A

Net Income

$140.00K

-74.9%

EBITDA

$169.00K

-71.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$4.02M

-1.5%

Total Debt

$968.00K

-27.1%

Accounts Receivable

$3.52M

+31.5%

Inventory

$3.62M

+85.2%

Long Term Debt

$566.00K

-41.6%

Short Term Debt

$402.00K

+12.3%

Return on Assets

5.63%

N/A

Return on Invested Capital

6.01%

N/A

Free Cash Flow

-$1.67M

-618.9%

Operating Cash Flow

-$1.67M

-618.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ONMDOneMedNet Corporation
$0.61+2.23%
OTLKOutlook Therapeutics, Inc.
$1.41+6.44%
HOWLWerewolf Therapeutics, Inc.
$0.43+18.55%
SPRBSpruce Biosciences, Inc.
$43.08-4.25%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
SOFISoFi Technologies
$16.46-0.01%
TAT&T
$24.13+0.05%

Questions About NEPH

What is the current price of Nephros?

Nephros is trading at $3.67 per share.

What is the 52-week range for Nephros?

Over the past 52 weeks, Nephros has traded between $2.66 and $6.42.

How much debt does Nephros have?

As of the most recent reporting period, Nephros reported total debt of $968.00K.

How much cash does Nephros have on hand?

Nephros reported $4.02M in cash and cash equivalents in its most recent financial results.

What is Nephros’s dividend yield?

Nephros does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services